Literature DB >> 3147192

Skeletal muscle and whole body protein turnover in cardiac cachexia: influence of branched-chain amino acid administration.

W L Morrison1, J N Gibson, M J Rennie.   

Abstract

Muscle protein wasting commonly accompanies severe heart failure. The mechanism of this so-called cardiac cachexia has been investigated in eight patients with an average body weight decrement of 19%, whose results have been compared with those from 11 healthy control subjects. Exchanges of tyrosine and 3-methylhistidine across leg tissue were used as specific indicators of net protein balance and myofibrillar protein breakdown, respectively. Whole body protein turnover was measured using a stable isotope labelling technique with L-[1-13C]leucine as tracer. In patients with cardiac cachexia there were greater values, relative to those values in normal control subjects, of leg efflux of tyrosine (-8.1 +/- 0.6 nmol 100 ml leg tissue-1 min-1 vs. -4.2 +/- 0.3 nmol 100 ml-1 min-1 (P less than 0.01) and of 3-methylhistidine (-0.8 +/- 0.1 nmol 100 ml leg tissue-1 min-1 vs. -0.1 +/- 0.02 nmol 100 ml-1 min-1 (P less than 0.005), mean +/- SEM). The results suggest that in patients with cardiac cachexia the state of net negative protein balance across leg tissue is associated with an increased rate of myofibrillar protein breakdown. In cardiac cachexia, neither efflux of tyrosine (-8.4 +/- 0.7 nmol 100 ml leg tissue-1 min-1) nor of 3-methylhistidine (-1.0 +/- 0.2 nmol 100 ml leg tissue-1 min-1) were significantly altered by branched-chain amino acid (BCAA) infusion to plasma concentrations of 1300 +/- 14 mumol ml-1, i.e., four times normal plasma values (282 +/- 11 mumol ml-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147192     DOI: 10.1111/j.1365-2362.1988.tb01282.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  13 in total

1.  Amino acid flooding doses for measuring rates of protein synthesis.

Authors:  A L Schaefer; S L Scott
Journal:  Amino Acids       Date:  1993-02       Impact factor: 3.520

2.  Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation.

Authors:  Michael J Toth; Martin M LeWinter; Philip A Ades; Dwight E Matthews
Journal:  Clin Sci (Lond)       Date:  2010-08-17       Impact factor: 6.124

Review 3.  Peripheral circulatory adaptations to pump failure of the heart.

Authors:  H Drexler
Journal:  Br Heart J       Date:  1994-08

4.  Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy.

Authors:  Danny Alexander; Raffaella Lombardi; Gabriela Rodriguez; Matthew M Mitchell; Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-12-14       Impact factor: 4.686

Review 5.  Cachexia in malaria and heart failure: therapeutic considerations in clinical practice.

Authors:  M E Onwuamaegbu; M Henein; A J Coats
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 6.  Diagnosis and management of heart failure in the elderly.

Authors:  D King
Journal:  Postgrad Med J       Date:  1996-10       Impact factor: 2.401

Review 7.  Skeletal muscle protein metabolism in human heart failure.

Authors:  Damien M Callahan; Michael J Toth
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-01       Impact factor: 4.294

Review 8.  The management of heart failure: a matter of definition?

Authors:  A Harley
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

9.  Serological muscle loss biomarkers: an overview of current concepts and future possibilities.

Authors:  Anders Nedergaard; Morten A Karsdal; Shu Sun; Kim Henriksen
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-21       Impact factor: 12.910

10.  The overnight effect of dietary energy balance on postprandial plasma free amino acid (PFAA) profiles in Japanese adult men.

Authors:  Manabu Nishioka; Akira Imaizumi; Toshihiko Ando; Osamu Tochikubo
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.